Cell Biotech Co., Ltd. (KOSDAQ:049960)
South Korea
· Delayed Price · Currency is KRW 12,590
-60 (-0.47%)
At close: Mar 31, 2025, 3:30 PM KST
Cell Biotech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 49,913 | 53,787 | 50,526 | 46,873 | 45,582 | Upgrade
|
| Other Revenue | - | - | -0 | - | - | Upgrade
|
| Revenue | 49,913 | 53,787 | 50,526 | 46,873 | 45,582 | Upgrade
|
| Revenue Growth (YoY) | -7.20% | 6.46% | 7.79% | 2.83% | -0.82% | Upgrade
|
| Cost of Revenue | 14,102 | 15,139 | 12,854 | 11,399 | 11,309 | Upgrade
|
| Gross Profit | 35,811 | 38,649 | 37,672 | 35,475 | 34,273 | Upgrade
|
| Selling, General & Admin | 21,847 | 29,845 | 25,278 | 21,988 | 24,639 | Upgrade
|
| Research & Development | 4,332 | 3,725 | 3,559 | 3,500 | 3,329 | Upgrade
|
| Other Operating Expenses | 226.87 | 221.45 | 249.55 | 207.87 | 179.76 | Upgrade
|
| Operating Expenses | 29,015 | 36,453 | 31,621 | 28,218 | 30,606 | Upgrade
|
| Operating Income | 6,796 | 2,195 | 6,051 | 7,257 | 3,667 | Upgrade
|
| Interest Expense | -60.88 | -61.95 | -37.49 | -42.48 | -49.28 | Upgrade
|
| Interest & Investment Income | 3,112 | 3,180 | 860.17 | 1,103 | 700.01 | Upgrade
|
| Earnings From Equity Investments | - | -82.2 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 5,093 | 698.5 | 2,990 | 3,325 | -2,246 | Upgrade
|
| Other Non Operating Income (Expenses) | 84.34 | 1,162 | 309.01 | 306.97 | 372.3 | Upgrade
|
| EBT Excluding Unusual Items | 15,024 | 7,092 | 10,173 | 11,950 | 2,444 | Upgrade
|
| Gain (Loss) on Sale of Investments | 575.56 | -211.19 | - | 111.68 | -50.69 | Upgrade
|
| Gain (Loss) on Sale of Assets | 10.14 | -0.26 | -0.91 | 29.05 | 9.48 | Upgrade
|
| Pretax Income | 15,610 | 6,880 | 10,172 | 12,090 | 2,402 | Upgrade
|
| Income Tax Expense | 483.01 | 576.36 | 1,891 | 1,707 | -786.7 | Upgrade
|
| Net Income | 15,127 | 6,304 | 8,281 | 10,383 | 3,189 | Upgrade
|
| Net Income to Common | 15,127 | 6,304 | 8,281 | 10,383 | 3,189 | Upgrade
|
| Net Income Growth | 139.97% | -23.87% | -20.25% | 225.58% | -55.90% | Upgrade
|
| Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 7 | 7 | 7 | 7 | 7 | Upgrade
|
| Shares Change (YoY) | 0.00% | -0.73% | -2.50% | -0.32% | -4.25% | Upgrade
|
| EPS (Basic) | 2210.00 | 921.00 | 1201.04 | 1468.32 | 449.56 | Upgrade
|
| EPS (Diluted) | 2210.00 | 921.00 | 1201.00 | 1468.00 | 449.56 | Upgrade
|
| EPS Growth | 139.96% | -23.31% | -18.19% | 226.54% | -53.94% | Upgrade
|
| Free Cash Flow | 18,138 | 6,264 | 10,445 | 14,044 | 6,485 | Upgrade
|
| Free Cash Flow Per Share | 2649.95 | 915.17 | 1515.03 | 1985.94 | 914.17 | Upgrade
|
| Dividend Per Share | - | - | 450.000 | 450.000 | 450.000 | Upgrade
|
| Dividend Growth | - | - | - | - | -25.00% | Upgrade
|
| Gross Margin | 71.75% | 71.85% | 74.56% | 75.68% | 75.19% | Upgrade
|
| Operating Margin | 13.62% | 4.08% | 11.98% | 15.48% | 8.04% | Upgrade
|
| Profit Margin | 30.31% | 11.72% | 16.39% | 22.15% | 7.00% | Upgrade
|
| Free Cash Flow Margin | 36.34% | 11.65% | 20.67% | 29.96% | 14.23% | Upgrade
|
| EBITDA | 10,668 | 6,100 | 9,689 | 11,046 | 7,352 | Upgrade
|
| EBITDA Margin | 21.37% | 11.34% | 19.18% | 23.57% | 16.13% | Upgrade
|
| D&A For EBITDA | 3,872 | 3,904 | 3,638 | 3,789 | 3,685 | Upgrade
|
| EBIT | 6,796 | 2,195 | 6,051 | 7,257 | 3,667 | Upgrade
|
| EBIT Margin | 13.62% | 4.08% | 11.98% | 15.48% | 8.04% | Upgrade
|
| Effective Tax Rate | 3.09% | 8.38% | 18.59% | 14.12% | - | Upgrade
|
| Advertising Expenses | 5,249 | 11,977 | 9,134 | 6,632 | 6,817 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.